Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Advances and Novel Treatment Options in Metastatic Melanoma
| Advances and Novel Treatment Options in Metastatic Melanoma |
| Autore | Facchiano Antonio |
| Pubbl/distr/stampa | Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 |
| Descrizione fisica | 1 electronic resource (528 p.) |
| Soggetto topico | Medicine |
| Soggetto non controllato |
melanoma
invasion WNT5A MARCKS phosphorylation MANS peptide nanoparticles cell therapy tumor microenvironment sex/gender sex-hormones immunity microRNAs immunotherapy BRAF-mutant melanoma BRAF inhibitor mechanism of action targeted therapy tumour microenvironment plasmacytoid dendritic cells lactate dehydrogenase TLR interferon CXCL10 TPC2 HIPPO SOCE metastasis essential oils angiogenesis apoptosis uveal melanoma (UM) metastatic uveal melanoma (mUM) prognostication adjuvant therapy metastatic therapy metastatic dormancy liver-directed-therapies targeted-therapy combined therapy protein tyrosine phosphatase PTPs inhibitors melanoma immune infiltrate BRAF inhibitors microenvironment resistance therapy therapeutic resistance exosomes extracellular vesicles diagnosis prognosis ctDNA liquid biopsy prediction patient stratification BRAF arthralgia rheumatoid arthritis carbonic anhydrase hedgehog cyclopamine small molecules acetazolamide motility metalloproteinases FAK cancer mucosal melanoma nivolumab pembrolizumab ipilimumab radiotherapy cholinergic system acetylcholine muscarinic receptors nicotinic receptors melanoma metastasis ShcD adaptor protein amoeboid motility Rac1 DOCK4 melanoma PDX target therapy cancer stem cells slow cycling phenotype drug resistance OXPHOS lipid metabolism cancer associated fibroblast melanomagenesis biomarkers checkpoint inhibitor PD-1 melanoma markers cytokines machine learning Support Vector Machine principal component analysis BCL2L10 STAT3 cytotoxicity survival ABT-737 Bcl-2 family ML258 HuR MITF metastases siRNA |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910557612103321 |
Facchiano Antonio
|
||
| Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Anticancer Drugs 2021
| Anticancer Drugs 2021 |
| Autore | Meegan Mary J |
| Pubbl/distr/stampa | Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 |
| Descrizione fisica | 1 electronic resource (594 p.) |
| Soggetto topico |
Research & information: general
Chemistry |
| Soggetto non controllato |
thymidylate synthase
cytotoxicity 1,2,3-triazole 1,3,4-oxadiazole 5-fluoruracil pemetrexed docking 3,4'-bis-guanidino 3-amino-4'-guanidino diphenyl ether phenyl pyridyl ether intramolecular hydrogen bond cancer cell viability HL-60 BRAF apoptosis thieno[2,3-d][1,2,3]triazine acetamide H1299 HER2 EGFR Bcl-2 inhibitors Indole-based analogues benzimidazole MTT cytotoxic assay cell cycle analysis DNA fragmentation ELISA solid/lipid nanoparticles phenstatin letrozole tubulin polymerisation inhibitor aromatase inhibitor breast cancer hybrid molecule dual-targeting molecule designed multiple ligand NaMSA cyclophosphamide histopathology testis urinary bladder anticancer agents enantioselective synthesis gastric adenocarcinoma tryptophanol concentration-guided dosing model informed dosing physiologically based pharmacokinetics sorafenib tyrosil-DNA-phosphodiesterase 1 adamantane resin acid TDP1 cytotoxic agents apoptosis induction HT-29 cells MDA-MB-231 cells mechanism prediction STAT inhibitors miR-21 hydrazide derivatives nitrogen scaffolds mitoxantrone cardiotoxicity inflammation oxidative stress age cumulative dose Trk NTRK tissue-agnostic larotrectinib entrectinib Trk fusion protein kinase inhibitors USFDA cancer patent review generic product doxazosin MD simulations combretastatin A-4 cytotoxic activity hybrid compounds indazole mucin MUC1 MUC16 immunotherapy cancer vaccine CAR (chimeric antigen receptor) ADC (antibody-drug conjugate) thiourea interleukin-6 trypan blue assay chalcones exportin-1 covalent binding CovDock anticancer activity xanthone in vitro in vivo isolation synthesis heterocyclic compound benzenesulfonamides imidazoles alkylated colony formation tumor spheroids HDAC inhibitors chalcone dual inhibitors carvedilol kidney toxicity 7-deaza-4'-thioadenosine derivatives multi-kinase inhibitor anticancer nucleoside Imiquimod drug efflux multidrug resistance Toll-Like Receptor |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910576874303321 |
|
Meegan Mary J
|
||
| Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
New Advances in Melanoma
| New Advances in Melanoma |
| Autore | Larribère Lionel |
| Pubbl/distr/stampa | Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 |
| Descrizione fisica | 1 electronic resource (148 p.) |
| Soggetto topico | Public health & preventive medicine |
| Soggetto non controllato |
melanoma
targeted therapies BRAF druggable mutations real-time PCR NGS assay immune escape microRNA transporter associated with antigen processing incidence population-based study epidemiology Spain skin cancer single-cell transcriptome sequencing treatment response pseudotime analysis treatment ubiquitination miRNAs embryogenesis melanoblasts melanoblast NF1 transcriptome RNAseq Trp-1 metastasis animal models lung mice |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910566475303321 |
|
Larribère Lionel
|
||
| Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Present and Future of Personalised Medicine for Endocrine Cancers
| Present and Future of Personalised Medicine for Endocrine Cancers |
| Autore | Ronchi Cristina L |
| Pubbl/distr/stampa | Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 |
| Descrizione fisica | 1 electronic resource (140 p.) |
| Soggetto topico | Medicine |
| Soggetto non controllato |
papillary thyroid cancer
SUV PET/CT BRAF V600E immune checkpoint inhibitors (ICIs) ipilimumab nivolumab prolactinoma Cushing's disease aggressive pituitary tumor aggressive PitNET aggressive pituitary adenoma pituitary carcinoma adrenocortical cancer adrenal adenomas adrenal tumors p53 p27 ki-67 reticulin mitotane adjuvant treatment recurrence recurrence free survival timing intratumoral heterogeneity thyroid tumor BRAF RET/PTC rearrangements RAS mutation adrenal cortex carcinoma angiogenesis gene expression osteopontin hyaluronan synthase 1 multikinase inhibitors sorafenib lenvatinib differentiated thyroid cancer radioiodine resistance predictive marker predictors response to treatment survival information needs and preferences focus group interview personalized medicine neuroendocrine tumours phaeochromocytoma paraganglioma molecular clusters |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910576879703321 |
|
Ronchi Cristina L
|
||
| Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||